Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

被引：0
|
作者：
Moussa, Charbel [1 ]
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
来源：
ANNALS OF NEUROLOGY | 2020年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
535
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [21] Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial
    Linder, Steven L.
    Mathew, Ninan T.
    Cady, Roger K.
    Finlayson, Gary
    Ishkanian, Gary
    Lewis, Donald W.
    HEADACHE, 2008, 48 (09): : 1326 - 1336
  • [22] Dose-response effects of cerebrolysin in Alzheimer's disease patients: A randomized, double-blind, placebo-controlled trial
    Alvarez, XA
    Cacabelos, R
    Vargas, M
    Aleixandre, M
    Linares, C
    Granizo, E
    Moessler, H
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S383 - S383
  • [23] The effects of fenugreek seed extract supplementation in patients with Alzheimer's disease: A randomized, double-blind, placebo-controlled trial
    Foroumandi, Elaheh
    Javan, Roghayeh
    Moayed, Leili
    Fahimi, Hossein
    Kheirabadi, Fereshteh
    Neamatshahi, Mahboubeh
    Shogofteh, Fazeleh
    Zarghi, Azam
    PHYTOTHERAPY RESEARCH, 2023, 37 (01) : 285 - 294
  • [24] A Randomized, Double-Blind, Placebo-Controlled Trial of Camicinal in Parkinson's Disease
    Marrinan, Sarah L.
    Otiker, Tal
    Vasist, Lakshmi S.
    Gibson, Rachel A.
    Sarai, Bhopinder K.
    Barton, Matthew E.
    Richards, Duncan B.
    Hellstrom, Per M.
    Nyholm, Dag
    Dukes, George E.
    Burn, David J.
    MOVEMENT DISORDERS, 2018, 33 (02) : 329 - 332
  • [25] A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
    Kieburtz, Karl
    McGarry, Andrew
    McDermott, Michael
    Kayson, Elise
    Harrison, Madaline
    Marder, Karen
    Walker, Francis
    MOVEMENT DISORDERS, 2013, 28 (10) : 1407 - 1415
  • [26] Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Klein, David J.
    Battelino, Tadej
    Chatterjee, D. J.
    Jacobsen, Lisbeth V.
    Hale, Paula M.
    Arslanian, Silva
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (10) : 679 - 687
  • [27] Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial
    Liu, Xiaoyan
    Zhang, Rui
    Li, Rong
    Wu, Qiong
    Pan, Chao
    Yu, Xiangqing
    Liu, Yuhui
    Wang, Benjie
    Yu, Shuwen
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (12)
  • [28] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial
    Jing, Shan
    Xu, Ranchi
    Yang, Kexu
    Liu, Wenfang
    Zhang, Leduo
    Ke, Ying
    Xia, Guangxin
    Lin, Yang
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 735 - +
  • [29] SAFETY AND TOLERABILITY OF MICROBIAL INULINASE SUPPLEMENTATION IN HEALTHY ADULTS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Garvey, Sean M.
    LeMoire, Ashley
    Wang, Jun
    Lin, Lois
    Sharif, Bisma
    Bier, Anthony
    Baisley, Joshua
    Tinker, Kelly M.
    Boyd, Robert C.
    GASTROENTEROLOGY, 2024, 166 (05) : S876 - S876
  • [30] Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
    Ballard, Clive
    Banister, Carol
    Khan, Zunera
    Cummings, Jeffrey
    Demos, George
    Coate, Bruce
    Youakim, James M.
    Owen, Randall
    Stankovic, Srdjan
    LANCET NEUROLOGY, 2018, 17 (03): : 213 - 222
12345